Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 23Plasma cell 17Lymphoid 16Myeloid 13CNS 6Classical hematology 4Other neoplasm 2Gastrointestinal 2Sarcoma 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Specimen Handling 38Magnetic Resonance Spectroscopy 32Cyclophosphamide 27Doxorubicin 24Temozolomide 23Biopsy 23pembrolizumab 22Radiotherapy 19X-Rays 18Radiation 18Nivolumab 16Vincristine 14Irinotecan 13Phantoms, Imaging 12Ifosfamide 12Gemcitabine 11fludarabine 10cabozantinib 10atezolizumab 10Ipilimumab 10Bevacizumab 9liposomal doxorubicin 8Paclitaxel 8Immunoglobulin G 8Surgical Procedures, Operative 7Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melphalan × Sarcoma × 90 days × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡